

Date and Time: *7 June 2013, 1000 - 1600*

Minutes: Confirmed

Guideline Development Group Meeting 4

Place: *National Clinical Guidelines Centre,
180 Great Portland Street, London, W1W 5QZ*

Present:

GDG

Shuaib Nasser(Chair) (SN)
Alice Osborne (AO)
James Larcombe (JL)
Mandy East (ME)
Mike Arden-Jones (MAJ)
Nicola Mundy (NM)
Paul Whitaker (PW)
Pamela Ewan (PE)

COOPTEE

Nigel Harper (NH)

NCGC

Carlos Sharpin (CS)
Gill Ritchie (GR)
Grace Marsden (GM)
Kathy De Mott (KDM)
Martin Harker (MH)
Tamara Diaz (TD)

Apologies:

David Cousins (DC)
George Du Toit (GDT)
Andrew Williams (AW)

In attendance:

NICE Staff:	Caroline Keir (CK)	
-------------	--------------------	--

Observers:

NICE/NCGC Staff:	None	
------------------	------	--

Notes

1. Welcome and Declarations of Interest: SN welcomed the group to the fourth meeting of this GDG. There were no formal apologies. The group was introduced to the GDG Cooptee Anaesthetist, NH. The Chair asked all GDG members to declare any relevant conflicts of interest. All GDG members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interests that would present conflicts in the development of this guideline. NH reported the completion of a project related to a muscle relaxant drug for which he had received a research grant. NH was asked to submit a written declaration related to his research grant. Additionally, he holds shares in GlaxoSmithKline; this was mentioned for the group's information.
2. Confirmation of the Minutes of GDG 3: The GDG confirmed the accuracy of the circulated minutes.
3. Evidence Review: The GDG heard evidence related to the following clinical questions:
 - a. What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to beta-lactams?
 - b. What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to NSAIDs?
 - c. What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to local anaesthetics?
 - d. What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected anaphylaxis due to drug allergy during general anaesthesia?
4. Review Protocols: Review protocols were finalised for the following clinical areas:
 - a. Management
5. Close of business: There being no further business the meeting ended at 4:00 p.m.

Date, time and venue of the next meeting

6. Friday 19 July 2013, 1000 to 1600 at the National Clinical Guidelines Centre, 180 Great Portland Street, London, W1W 5QZ.